uniQure (NASDAQ:QURE) Receives $40.00 Consensus Price Target from Brokerages

uniQure (NASDAQ:QURE) has earned a consensus recommendation of “Buy” from the ten brokerages that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $40.00.

QURE has been the topic of a number of recent analyst reports. Leerink Partners boosted their target price on shares of uniQure from $26.00 to $44.00 and gave the stock an “outperform” rating in a report on Wednesday, December 11th. HC Wainwright upped their target price on shares of uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a report on Monday, January 27th. Guggenheim reiterated a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. StockNews.com raised uniQure to a “sell” rating in a research report on Wednesday. Finally, The Goldman Sachs Group raised their price objective on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research report on Thursday, December 12th.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $7.63, for a total value of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.74% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On uniQure

Several hedge funds have recently bought and sold shares of the company. abrdn plc boosted its position in shares of uniQure by 381.7% during the 3rd quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock worth $9,510,000 after acquiring an additional 1,528,581 shares in the last quarter. Franklin Resources Inc. bought a new stake in uniQure during the third quarter worth $7,360,000. Point72 Asset Management L.P. boosted its holdings in shares of uniQure by 336.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after purchasing an additional 752,889 shares in the last quarter. FMR LLC increased its stake in shares of uniQure by 8,056.6% in the 3rd quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares during the last quarter. Finally, Privium Fund Management B.V. raised its holdings in shares of uniQure by 16.3% during the 3rd quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after buying an additional 104,500 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Stock Performance

QURE opened at $16.13 on Monday. The business’s 50-day simple moving average is $14.29 and its 200 day simple moving average is $9.09. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The firm has a market capitalization of $786.18 million, a PE ratio of -3.25 and a beta of 0.39.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, sell-side analysts expect that uniQure will post -3.75 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.